Loading…
Jyong Biotech Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -76.1% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HUMAHumacyte, Inc. | $0.65 | — | 12.5x | — | -547.87% | $180.6M |
| XGNExagen Inc | $7.39 | — | 14.6x | — | -113.82% | $179.03M |
| NERVMinerva Neurosciences, Inc. | $3.81 | — | — | — | — | $181.92M |
| ANTXAN2 Therapeutics, Inc. | $4.83 |
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Company description provided by Yahoo Finance.
| — |
| 2.3x |
| — |
| -50.12% |
| $182.27M |
| VYGRVoyager Therapeutics, Inc. | $2.87 | — | 1.0x | — | -54.09% | $176.84M |
| MSLESatellos Bioscience Inc. | $8.66 | — | 3.0x | — | -70.45% | $183.73M |